In previous investigations, we have found that the liver appears to be the major source of cholesterol in the human fetus, and, in particular, a principal source of circulating low density lipoprotein-cholesterol (LDL-C). LDL-C plasma levels are low in the normal fetus, most likely due to the rapid uptake and metabolism by the fetal adrenal as precursor for steroid hormone biosynthesis. In contrast, in the anencephalic fetus the adrenals are atrophic, the rate of estrogen and glucocorticoid production is low, and the levels of LDL-C in fetal plasma are high. The purpose of the present investigation was to determine the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the primary rate-limiting enzyme of cholesterol biosynthesis, in anencephalic liver and normal fetal liver. We found that the specific activity of HMG-CoA reductase in normal fetal liver microsomes was 0.428±0.054 nmol mevalonate formed times mg-' protein X min-' (mean±SE, n = 9). The rate of HMG-CoA reductase in anencephalic liver microsome preparations was 10-fold less (0.040±0.003) (mean±SE, n = 7) P < 0.001. Furthermore, we detected HMG-CoA reductase (97,000-mol wt protein) in normal human fetal liver after SDS PAGE and immunoblotting by using a monoclonal antibody directed against HMG-CoA reductase. We were unable to detect any significant quantity of HMG-CoA reductase protein in anencephalic fetal liver, which indicates that low reductase activity was due to low amounts of enzyme protein rather than inactive enzyme. In summary, we conclude that the low levels of cholesterol synthesis observed in anencephalic fetal liver are probably due to both the high levels of LDL-C in fetal plasma as well as the presence of low circulating levels of estrogens and glucocorticoids and that these factors regulate cholesterol synthesis both in vivo and in vitro in fetal liver. This occurs most probably by the modulation of the amount of HMG-CoA reductase, a primary rate-limiting and regulatory enzyme of the cholesterol biosynthetic sequence.
Introduction
We have previously suggested that the principal source of cholesterol in the fetus is by way of fetal synthesis of cholesterol de novo (1, 2) . Evidence to support this conclusion is derived from studies that demonstrate that no more than 20% of fetal cholesterol is derived from the maternal compartment (3) (4) (5) and that the fetal dietary source of cholesterol by way of swallowing amniotic fluid is negligible (6) . We reported in a survey of various Receivedfor publication 8 April 1985 and in revisedform 8 July 1985. human fetal tissues that the adrenal, liver, and testicular tissue exhibited high rates of cholesterol synthesis. On the basis of the size of the liver and its rapid rate of growth during fetal life as well as its high rate of cholesterol synthesis, we concluded that the liver is the major site of cholesterol formation in the fetus (2) . Furthermore, since the adult liver is a major source of lipoprotein biosynthesis and secretion, it seemed likely that in the fetus, the liver might be an important source of lipoproteincholesterol for extrahepatic tissues (7) . In fact, fetal liver tissue in vitro secretes lipoproteins (8) .
The fetal adrenal gland secretes large quantities of steroid hormones, and a major source of cholesterol for adrenal steroid hormone biosynthesis appears to be low density lipoproteincholesterol (LDL-C)' both in vitro and in vivo. The fetal adrenal gland is a major site of plasma LDL use and the activity of fetal adrenal is an important determinant of the levels of LDL in plasma (1, 9, 10) . In the normal human fetus, the adrenal glands secrete large quantities of steroid hormones, and, presumably, LDL-C uptake by the adrenals is high; as a consequence, LDL-C levels in fetal plasma are low. It follows that the rate of formation of cholesterol in fetal liver, if rate limiting, then may regulate in part the rate of steroid secretion by the fetal adrenal glands and the formation ofestrogens by the fetal-placental unit.
Estrogens and glucocorticoids, both found in large quantities in fetal plasma near term, stimulate cholesterol synthesis by fetal hepatocytes in vitro ( 1). In contrast, LDL-C inhibits cholesterol synthesis by hepatocytes maintained in vitro (12) . However, since fetal plasma LDL-C levels fall during gestation, the lack of negative feedback or cholesterol synthesis would support an overall increase in the rate of cholesterol biosynthesis by the fetal liver in vivo (13) .
In contrast to the normal fetus, in the anencephalic fetus the adrenals are atrophic and the rate of adrenal steroidogenesis and, consequently, the rate of estrogen production by the fetal placental unit are low (14, 15) . Furthermore, since the rate of steroidogenesis is low, the adrenals are not using LDL-C and the levels of LDL-C in fetal blood are up to three times that of the normal fetus throughout gestation (9, 10, 16, 17 
Results
The specific activities ofHMG-CoA reductase in seven individual anencephalic liver microsome preparations of fetuses between 17 and 46 wk gestational were determined. The values obtained ranged from 0.025 to 0.060 nmol mevalonate formed times mg-' microsomal protein X min-'. The reductase activities obtained did not vary significantly with gestational age. The specific activities of HMG-CoA reductase in nine individual normal fetal liver membrane preparations were determined. The range of gestational ages (12-18 wk) was less than that observed in the anencephalic fetuses, and the results obtained did not vary significantly within this gestational period (0.162-0.704 nmol mevalonate formed times mg-' microsomal protein X min-').
The average specific activity of HMG-CoA reductase in anencephalic fetal liver was 0.040±0.003 nmol X mg-' protein X min-' (mean±SE, n = 7). In contrast, the average specific activity of HMG-CoA reductase in normal fetal liver microsome preparations was 10-fold greater (0.428±0.054 nmol X mg-' protein X min-' [mean±SE, n = 9]) than the results obtained for anencephalic fetal liver (Fig. 1) .
To determine whether the reduction in reductase activity was due to an inactive enzyme or reduced amounts of enzyme protein, we used the immunoblotting technique to compare the amount of HMG-CoA reductase protein in fetal and anencephalic liver homogenates. In fetal liver homogenates, a 97,000-mol-wt protein was readily detected, but no similar protein was detectable in the anencephalic liver sample (Fig. 2) . Furthermore, there was no evidence of the lower molecular weight forms (53,000 or 66,000) of the enzyme (25) . The immunoblotted hu- Furthermore, we wished to determine whether the low level of enzyme (HMG-CoA reductase) was unique for anencephalic liver and the possible mechanisms whereby its activity was lowered by determining the activity or amount of other liver microsomal enzymes. As presented in Fig. 3 , the amounts of microsomal NADPH cytochrome c reductase were similar in normal and anencephalic liver microsomes. Similar results were also observed when the activities ofglucose-6-phosphatase were compared in anencephalic and normal fetal liver microsomes (Table I) . Discussion
In the present investigation, we observed a high rate ofcholesterol synthesis on the basis ofestimates ofthe specific activity ofHMG- CoA reductase in microsomal preparations of normal fetal liver (0.428±0.054 nmol X mg-' protein X min-'). These results were similar to those reported in a preliminary study (0.58±0.18 nmol X mg-' protein X min-) (20) . In our investigation, advancing gestational age did not influence levels of reductase activity.
The results ofour investigation demonstrate that the specific activity of HMG-CoA reductase was 10-fold less in anencephalic fetal liver microsomal preparations than observed in normal fetal liver. These differences were not due to inactive enzyme (27), but due rather to decreased amounts of enzyme protein.
A plausible mechanism to explain the low level in HMG-CoA reductase of anencephalic liver is the presence of a high concentration of LDL-C circulating in fetal plasma. LDL-C serves to down-regulate cholesterol synthesis in fetal liver hepatocytes in vitro (12) . In the normal fetus, LDL-C concentrations are one-third that observed in anencephalic fetal plasma (9) . Another explanation is that in the normal fetus, as gestation advances, the estrogen and glucocorticoids formed by the fetal-placental unit stimulate cholesterol synthesis in the fetal liver, as it has been previously demonstrated to occur in human fetal hepatocytes maintained in culture (1 1). Thus, in the absence of significant estrogen milieu and in the presence ofa high level of LDL-C, cholesterol synthesis in the anencephalic liver is low.
We observed similar activities of other liver microsomal enzymes, namely NADPH cytochrome c reductase and glucose-6-phosphatase in anencephalic and normal fetuses. These results suggest that the low activity of HMG-CoA reductase is not reflective of a general decrease of liver function. Moreover, we previously have measured similar rates of activity of estrone sulfate 16a-hydroxylase in microsomal preparations of anencephalic and normal fetal livers (28). Furthermore, the masses of livers of anencephalic fetuses are not significantly different to those of the normal fetus, except for a slight decrease near term (29) .
In conclusion, we were unable to determine if the low level of HMG-CoA reductase of anencephalic fetal liver was due singularly to the elevated LDL-C of fetal plasma or the deficiency of estrogens and glucocorticoids. These factors may both serve to regulate cholesterol synthesis both in vivo and in vitro in human fetal liver. The low activity of HMG-CoA reductase was not due to inactive (e.g., phosphorylated) enzyme, but to decreased enzyme protein.
